A multi-institutional study has mapped the genetic circuitry that determines whether CD8 killer T cells become durable immune defenders or lapse into exhaustion, and has shown that disabling two ...

Circulating CD28-KLRG1+CD8+ T cells as prognostic indicators in advanced NSCLC chemoimmunotherapy. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include ...

Ibrutinib was a breakthrough when it was first approved to treat R/R MCL in 2013, and a year later for patients with at least 1 prior treatment for chronic lymphocytic leukemia. However, its ...

For San Diego researchers and the wider immunotherapy community, the atlas functions as a practical roadmap. It does not promise instant cures, but it hands scientists clearer levers to test first in ...

As people age, their immune system function declines. T cell populations become smaller and can't react to pathogens as quickly, making people more susceptible to a variety of infections. To try to ...

Immune checkpoint blockades, or ICBs, have revolutionized treatment for various advanced cancers. However, their effectiveness has plateaued due to therapeutic resistance that renders ...

Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma Colorectal cancer (CRC) remains a major global health burden, being ...

A substantial proportion of patients with autoimmune diseases experienced a new side effect called local immune effector cell–associated toxicity syndromes (LICATS) after receiving chimeric antigen ...

CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has revolutionized how physicians treat cancer, especially blood cancers. “These patients can be cured ...

Non-communicable diseases such as diabetes, obesity, and metabolic syndrome are rising globally, while infectious diseases, ...